{"id":9900,"date":"2025-05-26T20:21:06","date_gmt":"2025-05-26T20:21:06","guid":{"rendered":"https:\/?page_id=9900"},"modified":"2025-06-06T17:00:17","modified_gmt":"2025-06-06T17:00:17","slug":"autoimmune-diseases-2","status":"publish","type":"page","link":"https:\/\/eutranslationalmedicine.org\/aii\/autoimmune-diseases-2\/","title":{"rendered":"Autoimmune Diseases"},"content":{"rendered":"\t\t
\n\t\t\t\t
\n\t\t\t\t\t
\n\t\t
\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\n\t\t\t\n\t\t\t\t\t\t
\n\n\t\t\t\t\t\t\t\t\t

\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tAutoimmune Diseases\t\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/h1>\n\t\t\t\t\n\t\t\t\t\n\t\t\t<\/div>\n\t\t\t\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Autoimmune diseases affect millions worldwide, driven by complex interactions between genetics, immune dysregulation, and environmental triggers. Biopharmaceutical companies are pioneering targeted therapies to suppress or reprogram harmful immune responses while preserving healthy immune function. These innovations aim to improve outcomes in chronic, often debilitating conditions such as rheumatoid arthritis, lupus, multiple sclerosis, and inflammatory bowel disease.<\/p>

Key Focus Areas:<\/strong><\/h5>

\u00a0<\/p>

  • Cytokine and Cytokine Receptor Targeting<\/strong>
    Inhibition of key inflammatory mediators such as TNF-\u03b1, IL-6, IL-17, IL-12\/23, and their receptors to dampen immune overactivation.<\/p><\/li>

  • JAK-STAT Pathway Inhibitors<\/strong>
    Oral small molecules targeting Janus kinases (JAK1\/2\/3, TYK2) to disrupt signaling cascades involved in inflammation.<\/p><\/li>

  • B-cell Modulation<\/strong>
    Therapies targeting CD20, BAFF, or plasma cells to reduce autoantibody production and B-cell-driven pathology.<\/p><\/li>

  • T-cell Co-Stimulation Blockade<\/strong>
    Inhibition of molecules like CD80\/CD86 and CD40L to prevent autoreactive T-cell activation.<\/p><\/li>

  • Immune Tolerance Induction<\/strong>
    Novel approaches to retrain the immune system, including tolerogenic vaccines, antigen-specific therapies, and regulatory T-cell enhancement.<\/p><\/li>

  • Microbiome Modulation<\/strong>
    Investigational therapies altering gut microbiota to restore immune balance in autoimmune and inflammatory conditions.<\/p><\/li>

  • Cell-Based Immunotherapies<\/strong>
    Use of Tregs, mesenchymal stem cells (MSCs), and engineered immune cells to actively suppress inflammation.<\/p><\/li>

  • Checkpoint Modulation in Autoimmunity<\/strong>
    Investigating whether pathways like PD-1\/PD-L1 and CTLA-4 can be leveraged to control immune overactivity.<\/p><\/li>

  • Complement System Inhibitors<\/strong>
    Targeting components of the complement cascade (e.g., C5, C3) in diseases like lupus nephritis and myasthenia gravis.<\/p><\/li>

  • Precision Biomarkers and Stratification<\/strong>
    Molecular diagnostics to predict response, stratify patients, and personalize autoimmune therapy selection.<\/p><\/li>

  • Others<\/p><\/li><\/ul><\/div><\/div>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"

    Autoimmune diseases affect millions worldwide, driven by complex interactions between genetics, immune dysregulation, and environmental triggers. Biopharmaceutical companies are pioneering targeted therapies to suppress or reprogram harmful immune responses while preserving healthy immune function. These innovations aim to improve outcomes in chronic, often debilitating conditions such as rheumatoid arthritis, lupus, multiple sclerosis, and inflammatory bowel […]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-9900","page","type-page","status-publish","hentry"],"acf":[],"yoast_head":"\nAutoimmune Diseases - Alliance for Immunology Innovations (AII)<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/eutranslationalmedicine.org\/aii\/autoimmune-diseases-2\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Autoimmune Diseases - Alliance for Immunology Innovations (AII)\" \/>\n<meta property=\"og:description\" content=\"Autoimmune diseases affect millions worldwide, driven by complex interactions between genetics, immune dysregulation, and environmental triggers. Biopharmaceutical companies are pioneering targeted therapies to suppress or reprogram harmful immune responses while preserving healthy immune function. These innovations aim to improve outcomes in chronic, often debilitating conditions such as rheumatoid arthritis, lupus, multiple sclerosis, and inflammatory bowel […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/eutranslationalmedicine.org\/aii\/autoimmune-diseases-2\/\" \/>\n<meta property=\"og:site_name\" content=\"Alliance for Immunology Innovations (AII)\" \/>\n<meta property=\"article:modified_time\" content=\"2025-06-06T17:00:17+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/eutranslationalmedicine.org\\\/aii\\\/autoimmune-diseases-2\\\/\",\"url\":\"https:\\\/\\\/eutranslationalmedicine.org\\\/aii\\\/autoimmune-diseases-2\\\/\",\"name\":\"Autoimmune Diseases - Alliance for Immunology Innovations (AII)\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/eutranslationalmedicine.org\\\/aii\\\/#website\"},\"datePublished\":\"2025-05-26T20:21:06+00:00\",\"dateModified\":\"2025-06-06T17:00:17+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/eutranslationalmedicine.org\\\/aii\\\/autoimmune-diseases-2\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/eutranslationalmedicine.org\\\/aii\\\/autoimmune-diseases-2\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/eutranslationalmedicine.org\\\/aii\\\/autoimmune-diseases-2\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/eutranslationalmedicine.org\\\/aii\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Autoimmune Diseases\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/eutranslationalmedicine.org\\\/aii\\\/#website\",\"url\":\"https:\\\/\\\/eutranslationalmedicine.org\\\/aii\\\/\",\"name\":\"Alliance for Immunology Innovations (AII)\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/eutranslationalmedicine.org\\\/aii\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Autoimmune Diseases - Alliance for Immunology Innovations (AII)","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/eutranslationalmedicine.org\/aii\/autoimmune-diseases-2\/","og_locale":"en_US","og_type":"article","og_title":"Autoimmune Diseases - Alliance for Immunology Innovations (AII)","og_description":"Autoimmune diseases affect millions worldwide, driven by complex interactions between genetics, immune dysregulation, and environmental triggers. Biopharmaceutical companies are pioneering targeted therapies to suppress or reprogram harmful immune responses while preserving healthy immune function. These innovations aim to improve outcomes in chronic, often debilitating conditions such as rheumatoid arthritis, lupus, multiple sclerosis, and inflammatory bowel […]","og_url":"https:\/\/eutranslationalmedicine.org\/aii\/autoimmune-diseases-2\/","og_site_name":"Alliance for Immunology Innovations (AII)","article_modified_time":"2025-06-06T17:00:17+00:00","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/eutranslationalmedicine.org\/aii\/autoimmune-diseases-2\/","url":"https:\/\/eutranslationalmedicine.org\/aii\/autoimmune-diseases-2\/","name":"Autoimmune Diseases - Alliance for Immunology Innovations (AII)","isPartOf":{"@id":"https:\/\/eutranslationalmedicine.org\/aii\/#website"},"datePublished":"2025-05-26T20:21:06+00:00","dateModified":"2025-06-06T17:00:17+00:00","breadcrumb":{"@id":"https:\/\/eutranslationalmedicine.org\/aii\/autoimmune-diseases-2\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/eutranslationalmedicine.org\/aii\/autoimmune-diseases-2\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/eutranslationalmedicine.org\/aii\/autoimmune-diseases-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/eutranslationalmedicine.org\/aii\/"},{"@type":"ListItem","position":2,"name":"Autoimmune Diseases"}]},{"@type":"WebSite","@id":"https:\/\/eutranslationalmedicine.org\/aii\/#website","url":"https:\/\/eutranslationalmedicine.org\/aii\/","name":"Alliance for Immunology Innovations (AII)","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/eutranslationalmedicine.org\/aii\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/eutranslationalmedicine.org\/aii\/wp-json\/wp\/v2\/pages\/9900","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/eutranslationalmedicine.org\/aii\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/eutranslationalmedicine.org\/aii\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/eutranslationalmedicine.org\/aii\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/eutranslationalmedicine.org\/aii\/wp-json\/wp\/v2\/comments?post=9900"}],"version-history":[{"count":8,"href":"https:\/\/eutranslationalmedicine.org\/aii\/wp-json\/wp\/v2\/pages\/9900\/revisions"}],"predecessor-version":[{"id":10047,"href":"https:\/\/eutranslationalmedicine.org\/aii\/wp-json\/wp\/v2\/pages\/9900\/revisions\/10047"}],"wp:attachment":[{"href":"https:\/\/eutranslationalmedicine.org\/aii\/wp-json\/wp\/v2\/media?parent=9900"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}